Alivus Life Sciences Limited (BOM:543322)

India flag India · Delayed Price · Currency is INR
1,008.60
-36.85 (-3.52%)
At close: Apr 28, 2026
-2.49%
Market Cap 123.68B
Revenue (ttm) 25.12B
Net Income (ttm) 5.44B
Shares Out n/a
EPS (ttm) 44.23
PE Ratio 22.75
Forward PE 17.39
Dividend 5.00 (0.48%)
Ex-Dividend Date Sep 1, 2025
Volume 6,909
Average Volume 5,539
Open 1,055.75
Previous Close 1,045.45
Day's Range 999.90 - 1,057.65
52-Week Range 830.00 - 1,224.00
Beta n/a
RSI 47.13
Earnings Date Apr 30, 2026

About Alivus Life Sciences

Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health,... [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 2001
Employees 2,203
Stock Exchange Bombay Stock Exchange
Ticker Symbol 543322
Full Company Profile

Financial Performance

In fiscal year 2025, Alivus Life Sciences's revenue was 23.87 billion, an increase of 4.54% compared to the previous year's 22.83 billion. Earnings were 4.86 billion, an increase of 3.13%.

Financial Statements

News

There is no news available yet.